207 related articles for article (PubMed ID: 36990678)
21. Pharmacoeconomic comparison of Helicobacter pylori eradication regimens.
Sancar M; Izzettin FV; Apikoglu-Rabus S; Besisik F; Tozun N; Dulger G
Pharm World Sci; 2006 Aug; 28(4):207-14. PubMed ID: 17066247
[TBL] [Abstract][Full Text] [Related]
22. The health economics of Helicobacter pylori infection.
Moayyedi P
Best Pract Res Clin Gastroenterol; 2007; 21(2):347-61. PubMed ID: 17382282
[TBL] [Abstract][Full Text] [Related]
23. Helicobacter pylori eradication regimens in an antibiotic high-resistance European area: A cost-effectiveness analysis.
Papaefthymiou A; Liatsos C; Georgopoulos SD; Apostolopoulos P; Doulberis M; Kyriakos N; Giakoumis M; Papadomichelakis M; Galanopoulos M; Katsinelos P; Rokkas T; Kountouras J
Helicobacter; 2020 Feb; 25(1):e12666. PubMed ID: 31692137
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of Helicobacter pylori eradication for the long-term management of duodenal ulcer in Canada.
O'Brien B; Goeree R; Mohamed AH; Hunt R
Arch Intern Med; 1995 Oct; 155(18):1958-64. PubMed ID: 7575049
[TBL] [Abstract][Full Text] [Related]
25. Helicobacter pylori eradication prior to initiation of long-term non-steroidal anti-inflammatory drug therapy in Chinese patients-a cost-effectiveness analysis.
You JH; Lau W; Lee IY; Yung M; Ching JY; Chan FK; Lee KK
Int J Clin Pharmacol Ther; 2006 Apr; 44(4):149-53. PubMed ID: 16625983
[TBL] [Abstract][Full Text] [Related]
26. Cost‑effectiveness Analysis of
Zheng H; Xie Q; Zhan M; Jin C; Li Q
Patient Prefer Adherence; 2021; 15():77-85. PubMed ID: 33519193
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of omeprazole and amoxicillin with either clarithromycin or metronidazole on eradication of Helicobacter pylori in Chinese peptic ulcer patients.
Sun WH; Ou XL; Cao DZ; Yu Q; Yu T; Hu JM; Zhu F; Sun YL; Fu XL; Su H
World J Gastroenterol; 2005 Apr; 11(16):2477-81. PubMed ID: 15832421
[TBL] [Abstract][Full Text] [Related]
28. Key topics in Helicobacter pylori eradication in the management of the dyspeptic patient: a panel discussion.
Kearney DJ; Mégraud F
Eur J Gastroenterol Hepatol; 2001 Aug; 13 Suppl 2():S17-21. PubMed ID: 11686229
[TBL] [Abstract][Full Text] [Related]
29. [Cost-effectiveness analysis of the eradication of Helicobacter pylori as treatment for duodenal ulcer].
Fernández Muñoz J; López de Andrés A; Zapater Hernández P; Abad Santos F
An Med Interna; 1998 Oct; 15(10):515-22. PubMed ID: 9844225
[TBL] [Abstract][Full Text] [Related]
30. Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age.
Briggs AH; Sculpher MJ; Logan RP; Aldous J; Ramsay ME; Baron JH
BMJ; 1996 May; 312(7042):1321-5. PubMed ID: 8646042
[TBL] [Abstract][Full Text] [Related]
31. Helicobacter pylori antimicrobial resistance during a 5-year period (2013-2017) in northern Spain and its relationship with the eradication therapies.
Cosme A; Torrente Iranzo S; Montes Ros M; Fernández-Reyes Silvestre M; Alonso Galán H; Lizasoain J; Bujanda L
Helicobacter; 2019 Feb; 24(1):e12557. PubMed ID: 30460730
[TBL] [Abstract][Full Text] [Related]
32. Is Helicobacter pylori eradication a cost-effective treatment of duodenal ulcer disease?
Carrere MO; Lamouliatte H; Ruszniewski P
Pharmacoeconomics; 1997 Mar; 11(3):216-24. PubMed ID: 10165311
[TBL] [Abstract][Full Text] [Related]
33. Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
Liou JM; Jiang XT; Chen CC; Luo JC; Bair MJ; Chen PY; Chou CK; Fang YJ; Chen MJ; Chen CC; Lee JY; Yang TH; Yu CC; Kuo CC; Chiu MC; Chen CY; Shun CT; Hu WH; Tsai MH; Hsu YC; Tseng CH; Chang CY; Lin JT; El-Omar EM; Wu MS;
Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):228-241. PubMed ID: 36549320
[TBL] [Abstract][Full Text] [Related]
34. Clinical and economic effects of population-based Helicobacter pylori screening to prevent gastric cancer.
Fendrick AM; Chernew ME; Hirth RA; Bloom BS; Bandekar RR; Scheiman JM
Arch Intern Med; 1999 Jan; 159(2):142-8. PubMed ID: 9927096
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness of Helicobacter pylori eradication therapy at a company occupational health clinic in Japan.
Yamasaki T
J UOEH; 2002 Jun; 24(2):161-76. PubMed ID: 12066584
[TBL] [Abstract][Full Text] [Related]
36. Screening and eradication of
Liou JM; Malfertheiner P; Lee YC; Sheu BS; Sugano K; Cheng HC; Yeoh KG; Hsu PI; Goh KL; Mahachai V; Gotoda T; Chang WL; Chen MJ; Chiang TH; Chen CC; Wu CY; Leow AH; Wu JY; Wu DC; Hong TC; Lu H; Yamaoka Y; Megraud F; Chan FKL; Sung JJ; Lin JT; Graham DY; Wu MS; El-Omar EM;
Gut; 2020 Dec; 69(12):2093-2112. PubMed ID: 33004546
[TBL] [Abstract][Full Text] [Related]
37. Helicobacter pylori eradication in long-term proton pump inhibitor users is highly cost-effective: economic analysis of the HELPUP trial.
Mason JM; Raghunath AS; Hungin AP; Jackson W
Aliment Pharmacol Ther; 2008 Dec; 28(11-12):1297-303. PubMed ID: 18793340
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and tolerability of first-line triple therapy with levofloxacin and amoxicillin plus esomeprazole or rabeprazole for the eradication of Helicobacter pylori infection and the effect of CYP2C19 genotype: a 1-week, randomized, open-label study in Chinese adults.
Pan X; Li Y; Qiu Y; Tang Q; Qian B; Yao L; Shi R; Zhang G
Clin Ther; 2010 Nov; 32(12):2003-11. PubMed ID: 21118735
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness analysis of different strategies for treating duodenal ulcer. Helicobacter pylori eradication versus antisecretory treatment.
Badia X; Segú JL; Ollé A; Brosa M; Monés J; García Ponte L
Pharmacoeconomics; 1997 Apr; 11(4):367-76. PubMed ID: 10166411
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the efficacy and tolerability of four different therapeutic regimens for the Helicobacter pylori eradication.
Tursi A; Cammarota G; Montalto M; Papa A; Cuoco L; Veneto GM; Cannizzaro O; Fedeli G; Gasbarrini G
Panminerva Med; 1996 Sep; 38(3):145-9. PubMed ID: 9009677
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
